 <h1>Lazanda Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>fentanyl</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about fentanyl. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Lazanda.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to fentanyl: lozenge/troche, spray, tablet</i></p><p>Other dosage forms:</p><ul><li>injection solution</li><li>nasal spray</li><li>transdermal patch device assisted, transdermal patch extended release</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Sublingual route (Spray)</p><p>Warning: Life-Threatening Respiratory Depression, Accidental Ingestion; Cytochrome P450 3A4 Interaction; Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants; Risk of Medication Errors; Addiction, Abuse, and Misuse; REMS; and Neonatal Opioid Withdrawal SyndromeSerious, life-threatening, and/or fatal respiratory depression has occurred. Monitor closely, especially upon initiation or following a dose increase. Due to the risk of fatal respiratory depression, fentanyl sublingual spray is contraindicated in opioid non-tolerant patients and in management of acute or postoperative pain, including headache/migraines.Accidental ingestion of fentanyl sublingual spray, especially by children, can result in a fatal overdose of fentanyl. Keep out of reach of children. Ensure proper storage and disposal.Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl.Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.When prescribing, do not convert patients on a mcg per mcg basis from any other oral transmucosal fentanyl product to fentanyl sublingual spray.When dispensing, do not substitute with any other fentanyl products.Fentanyl sublingual spray exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patientâ€™s risk before prescribing and monitor regularly for these behaviors and conditions.Fentanyl sublingual spray is available only through a restricted program called the TIRF REMS Access program. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors are required to enroll in the program.Prolonged use of fentanyl sublingual spray during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available..</p><p class="blackboxWarning-title">Buccal mucosa route (Film; Lozenge/Troche; Tablet)</p><p>Due to the risk of fatal respiratory depression, transmucosal fentanyl citrate is contraindicated in opioid non-tolerant patients and in management of acute or postoperative pain, including headache/migraines. Monitor for respiratory depression during treatment. Accidental ingestion of fentanyl can result in a fatal overdose, especially in children; keep out of reach of children. Use with CYP3A4 inhibitors or inducers may change fentanyl plasma levels resulting in a fatal overdose of fentanyl and monitoring is recommended. Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with inadequate alternative treatment options, limit dosage and duration to the minimum required, and monitor for respiratory depression and sedation. When prescribing, do not convert patients on a mcg per mcg basis from any other fentanyl products. When dispensing, do not substitute with any other fentanyl products. Fentanyl is a Schedule II controlled substance with abuse liability similar to other opioid analgesics. Assess risk prior to initiation and monitor for signs of misuse, abuse, and addiction during treatment. Only available through a restricted program called the Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy (TIRF REMS) Access program. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors are required to enroll in the program. Prolonged use during pregnancy may result in neonatal opioid withdrawal syndrome. If prolonged use is required in a pregnant woman, advise patient of potential fetal risk and ensure appropriate treatment will be available.</p><p class="blackboxWarning-title">Sublingual route (Tablet)</p><p>Due to the risk of fatal respiratory depression, sublingual fentanyl citrate is contraindicated in opioid non-tolerant patients and in management of acute or postoperative pain, including headache/migraines. Monitor for respiratory depression during treatment. Accidental ingestion of fentanyl can result in a fatal overdose, especially in children; keep out of reach of children. Use with CYP3A4 inhibitors or inducers may change fentanyl plasma levels resulting in fatal overdose and monitoring is recommended. Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with inadequate alternative treatment options, limit dosage and duration to the minimum required, and monitor for respiratory depression and sedation. When prescribing, do not convert patients on a mcg per mcg basis from any other fentanyl products. When dispensing, do not substitute with any other fentanyl products. Fentanyl is a Schedule II controlled substance with abuse liability similar to other opioid analgesics. Assess risk prior to initiation and monitor for signs of misuse, abuse, and addiction during treatment. Only available through a restricted program called the Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy (TIRF REMS) Access program. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors are required to enroll in the program. Prolonged use during pregnancy may result in neonatal opioid withdrawal syndrome. If prolonged use is required in a pregnant woman, advise patient of potential fetal risk and ensure appropriate treatment will be available.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, fentanyl (the active ingredient contained in Lazanda) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking fentanyl:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>confusion</li>
<li>convulsions</li>
<li>cough</li>
<li>decreased urine</li>
<li>difficult or labored breathing</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fainting</li>
<li>fever or chills</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>lightheadedness</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>mood changes</li>
<li>muscle pain or cramps</li>
<li>nausea or vomiting</li>
<li>nervousness</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pounding in the ears</li>
<li>rapid breathing</li>
<li>sneezing</li>
<li>sore throat</li>
<li>sunken eyes</li>
<li>swelling of the hands, ankles, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>wrinkled skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>change in walking and balance</li>
<li>clumsiness or unsteadiness</li>
<li>decreased awareness or responsiveness</li>
<li>decreased frequency of urination</li>
<li>headache</li>
<li>muscle twitching or jerking</li>
<li>pounding in the ears</li>
<li>rhythmic movement of the muscles</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>seizures</li>
<li>severe constipation</li>
<li>severe sleepiness</li>
<li>shakiness in the legs, arms, hands, or feet</li>
<li>slow or fast heartbeat</li>
<li>thinking abnormalities</li>
<li>trembling or shaking of the hands or feet</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking fentanyl:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Extremely shallow or slow breathing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of fentanyl may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement (stool)</li>
<li>difficulty with moving</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>irritability</li>
<li>lack or loss of strength</li>
<li>loss of interest or pleasure</li>
<li>muscle stiffness</li>
<li>pain in the joints</li>
<li>sleepiness or unusual drowsiness</li>
<li>tiredness</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>weight loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Changes in vision</li>
<li>excessive muscle tone</li>
<li>feeling of constant movement of self or surroundings</li>
<li>feeling of warmth or heat</li>
<li>flushing or redness of the skin, especially on the face and neck</li>
<li>irritation, pain, or sores at the site of application</li>
<li>itching skin</li>
<li>muscle tension or tightness</li>
<li>rash</li>
<li>sensation of spinning</li>
<li>sweating</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Tooth pain</li>
<li>trouble with gums</li>
<li>trouble with teeth</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fentanyl: buccal film, buccal tablet, compounding powder, injectable solution, intravenous solution, nasal spray, oral lozenge, oral transmucosal lozenge, sublingual spray, sublingual tablet, transdermal device, transdermal film extended release</i></p><h3>General</h3><p>The most commonly reported adverse reactions included headache, nausea, vomiting, ,dizziness, and constipation.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Somnolence, dizziness</p>
<p><b>Common</b> (1% to 10%): Sedation, pyrexia, fatigue, lethargy, tremor, headache, chills, irritability, malaise, confusion, abnormal thinking, anxiety, dysphoria</p>
<p><b>Uncommon</b> (0.1% to 1%): Hyperesthesia</p>
<p><b>Very rare</b> (less than 0.01%): Severe hemiplegic migraine</p>
<p><b>Frequency not reported</b>: Slurred speech, paresthesia, hypesthesia, tremor</p>
<p><b>Postmarketing reports</b>: Loss of consciousness, vertigo, coma, shock, convulsion<sup>[Ref]</sup></p><p>Cases of seizures have occasionally been reported, but some investigators have suggested that the seizure-like events reported may have been episodes of fentanyl induced-rigidity.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia</p>
<p><b>Uncommon</b> (0.1% to 1%): Sinus tachycardia, chest pain, hypertension, hypotension, palpitations</p>
<p><b>Rare</b> (less than 0.1%): Arrhythmias, cardiac arrest</p>
<p><b>Frequency not reported</b>: Syncope, vasodilation, bradycardia, bigeminy, myocardial infarct</p>
<p><b>Postmarketing reports</b>: Circulatory depression<sup>[Ref]</sup></p><p>One report has suggested that epidural fentanyl may mask the pain of myocardial ischemia in patients treated with fentanyl for other reasons.  Another report has suggested that QTc interval prolongation may occur in some patients receiving the related narcotic sufentanil.  Another report has implicated fentanyl as a potential cause of pulsus alternans in a patient with aortic stenosis and congestive heart failure.</p>
<p></p>
<p>Nevertheless, fentanyl has been advocated by some as a satisfactory agent for coronary artery surgery.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (18%), vomiting (10%), constipation</p>
<p><b>Common</b> (1% to 10%): Dry mouth, abdominal distension, gastritis, dysphagia, dyspepsia, gastroesophageal reflux disease, ascites, hematemesis, taste perversion, abdominal pain, dehydration, anorexia, cachexia, vomiting, dry mouth, mouth ulcers/stomatitis, tongue edema </p>
<p><b>Uncommon</b> (0.1% to 1%): Abdomen enlarged, flatulence</p>
<p><b>Rare</b> (less than 0.1%): Choledochoduodenal sphincter spasm</p>
<p><b>Frequency not reported</b>: Diarrhea</p>
<p><b>Postmarketing reports</b>: Ileus, dental caries, tooth loss, gingival recession, gingivitis, gingival bleeding, lip edema, pharyngeal edema, gum bleeding, ulcer<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Urinary retention</p>
<p><b>Very rare</b> (less than 0.01%): Priapism</p>
<p><b>Frequency not reported</b>: Urinary tract infection, urination impaired, hematuria, urinary urgency, dysuria<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b>(10% or more): Iontophoretic transdermal system: Application site reaction-Erythema (14%)</p>
<p><b>Common</b> (1% to 10%): Application site irritation, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Hyperhidrosis, rash</p>
<p><b>Rare</b> (less than 0.1%): Systemic rashes</p>
<p><b>Frequency not reported</b>: vesicles, papules/pustules, dry and flaky skin, vesiculobullous rash wound site oozing/bleeding, wound site inflammation/erythema</p>
<p><b>Postmarketing reports</b>: Application site discharge, application site bleeding, application site infection, rash and scab, erosion, hyperesthesia, application site necrosis<sup>[Ref]</sup></p><p>Approximately 60% of patients had some redness at the skin site 24-hours after removal of the iontophoretic transdermal system.  The majority of skin events were categorized as mild, erythema and papules were observed; 2 patients had hyperpigmentation at the application site lasting 2 to 3 weeks; 3 patients had a rectangular mark at the application site which persisted for up to 3 months.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The hemolysis observed may have been related to rapid injection of large volumes of hypotonic fentanyl (the active ingredient contained in Lazanda) solution.  The authors therefore recommend slower injection rates and/or mixture in isotonic fluid.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Anemia, neutropenia, lymphadenopathy, thrombocytopenia, leukopenia, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood glucose increased, blood lactate increased, hypoalbuminemia, vasodilation<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Oral candidiasis, cellulitis, pneumonia, urinary tract infection, oral herpes, gastroenteritis, laryngitis</p>
<p><b>Very rare</b> (less than 0.01%): Recurrent herpes simplex infection following epidural administration<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Asthenia, peripheral edema, weight decreased, hypokalemia, hyponatremia, hypocalcemia</p>
<p><b>Very rare</b> (less than 0.01%): Syndrome of inappropriate antidiuretic hormone</p>
<p><b>Frequency not reported</b>: abnormal healing, dehydration<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hot flush<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Fall/accidental injury, back pain, arthralgia, joint swelling, muscular weakness, myoclonus, involuntary muscle contractions, muscle rigidity (involving the respiratory musculature including the glottis)</p>
<p><b>Frequency not reported</b>: Leg cramps, myalgia</p>
<p><b>Postmarketing reports</b>: Abnormal gait/incoordination<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Vision blurred, dry eye</p>
<p><b>Rare</b> (less than 0.1%): Abnormal vision<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, confusional state, hallucination, insomnia</p>
<p><b>Uncommon</b> (0.1% to 1%): Anxiety, agitation, restlessness, agitation, disorientation, abnormal dreams, depersonalization, depression, emotional lability, euphoria, delirium</p>
<p><b>Frequency not reported</b>: Nervousness<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea, rhinitis, yawning, respiratory distress, apnea, bradypnea, hypoventilation, respiratory depression</p>
<p><b>Uncommon</b> (0.1% to 1%): Cough, increased bronchial secretion, dysphonia, pharyngolaryngeal pain, wheezing, hypoxia, exertional dyspnea</p>
<p><b>Very rare</b> (less than 0.01%): Acute noncardiogenic pulmonary edema</p>
<p><b>Frequency not reported</b>: Asthma, hiccup, atelectasis, hyperventilation</p>
<p><b>Postmarketing reports</b>: Respiratory arrest<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Ionsys (fentanyl)." Ortho McNeil Pharmaceutical, Raritan, NJ. </p><p id="ref_2">2. Weinger MB, Swerdlow NR, Millar WL "Acute postoperative delirium and extrapyramidal signs in a previously healthy parturient." Anesth Analg 67 (1988): 291-5</p><p id="ref_3">3. Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994): 251</p><p id="ref_4">4. Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986): 979-81</p><p id="ref_5">5. Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991): 1153-5</p><p id="ref_6">6. Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983): 858-9</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989): 852-62</p><p id="ref_9">9. Mirenda J, Tabatabai M, Wong K "Delayed and prolonged rigidity greater than 24 h following high-dose fentanyl anesthesia." Anesthesiology 69 (1988): 624-5</p><p id="ref_10">10. Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985): 205</p><p id="ref_11">11. Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982): 1020-1</p><p id="ref_12">12. Arandia HY, Patil VU "Glottic closure following large doses of fentanyl." Anesthesiology 66 (1987): 574-5</p><p id="ref_13">13. Bernstein KJ, Klausner MA "Potential dangers related to transdermal fentanyl (duragesic(r)) when used for postoperative pain." Dis Colon Rectum 37 (1994): 1339-40</p><p id="ref_14">14. Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976): 464-8</p><p id="ref_15">15. Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981): 362-3</p><p id="ref_16">16. Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983): 78</p><p id="ref_17">17. Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994): 1169-80</p><p id="ref_18">18. Crawford RD, Baskoff JD "Fentanyl-associated delirium in man." Anesthesiology 53 (1980): 168-9</p><p id="ref_19">19. Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992): 558-62</p><p id="ref_20">20. Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984): 387-8</p><p id="ref_21">21. Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990): 243-5</p><p id="ref_22">22. Hays LR, Stillner V, Littrell R "Fentanyl dependence associated with oral ingestion." Anesthesiology 77 (1992): 819-20</p><p id="ref_23">23. Streisand JB, Bailey PL, LeMaire L, Ashburn MA, Tarver SD, Varvel J, Stanley TH "Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, duration, and plasma concentrations." Anesthesiology 78 (1993): 629-34</p><p id="ref_24">24. Gil-Gouveia R,  Wilkinson PA,  Kaube H "Severe hemiplegic migraine attack precipitated by fentanyl sedation for esophagogastroscopy." Neurology 63 (2004): 2446-7</p><p id="ref_25">25. Steinberg RB, Gilman DE, Johnson F, 3d "Acute toxic delirium in a patient using transdermal fentanyl." Anesth Analg 75 (1992): 1014-6</p><p id="ref_26">26. Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991): 712</p><p id="ref_27">27. Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994): 820-1</p><p id="ref_28">28. Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987): 442-3</p><p id="ref_29">29. Oden RV, Karagianes TG "Postoperative myocardial ischemia possibly masked by epidural fentanyl analgesia." Anesthesiology 74 (1991): 941-3</p><p id="ref_30">30. Freeman AB, Steinbrook RA "Recurrence of pulsus alternans after fentanyl injection in a patient with aortic stenosis and congestive heart failure." Can Anaesth Soc J 32 (1985): 654-7</p><p id="ref_31">31. Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980): 162-3</p><p id="ref_32">32. Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982): 308-15</p><p id="ref_33">33. Sosis M "Fentanyl and emesis." Can Anaesth Soc J 32 (1985): 314-5</p><p id="ref_34">34. McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978): 437</p><p id="ref_35">35. White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992): 576-82</p><p id="ref_36">36. Gaskey NJ, Ferriero L, Pournaras L, Seecof J "Use of fentanyl markedly increases nausea and vomiting in gynecological short stay patients." AANA J 54 (1986): 309-11</p><p id="ref_37">37. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_38">38. Chin JL, Sharpe JR "Priapism and anesthesia: new considerations." J Urol 130 (1983): 371</p><p id="ref_39">39. Stoukides CA, Stegman M "Diffuse rash associated with transdermal fentanyl." Clin Pharm 11 (1992): 222</p><p id="ref_40">40. Bennett MJ, Anderson LK, McMillan JC, Ebertz JM, Hanifin JM, Hirshman CA "Anaphylactic reaction during anaesthesia associated with positive intradermal skin test to fentanyl." Can Anaesth Soc J 33 (1986): 75-8</p><p id="ref_41">41. Zucker-Pinchoff B, Ramanathan S "Anaphylactic reaction to epidural fentanyl." Anesthesiology 71 (1989): 599-601</p><p id="ref_42">42. Furuya H, Okumura F "Hemolysis after administration of high-dose fentanyl." Anesth Analg 65 (1986): 207-8</p><p id="ref_43">43. Valley MA, Bourke DL, McKenzie AM "Recurrence of thoracic and labial herpes simplex virus infection in a patient receiving epidural fentanyl." Anesthesiology 76 (1992): 1056-7</p><p id="ref_44">44. Kokko H,  Hall PD,  Afrin LB "Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion." Pharmacotherapy 22 (2002): 1188-92</p><p id="ref_45">45. Soto J, Sacristan JA, Alsar MJ "Pulmonary oedema due to fentanyl?." Anaesthesia 47 (1992): 913-4</p><p id="ref_46">46. Bohrer H, Fleischer F, Werning P "Tussive effect of a fentanyl bolus administered through a central venous catheter." Anaesthesia 45 (1990): 18-21</p><p id="ref_47">47. Tweed WA, Dakin D "Explosive coughing after bolus fentanyl injection." Anesth Analg 92 (2001): 1442-3</p><p id="ref_48">48. Ananthanarayan C "Tussive effect of fentanyl." Anaesthesia 45 (1990): 595</p><p id="ref_49">49. Phua WT, Teh BT, Jong W, Lee TL, Tweed WA "Tussive effect of a fentanyl bolus." Can J Anaesth 38 (1991): 330-4</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Lazanda (fentanyl)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En EspaÃ±ol</li>
<li>2 Reviews</li>
<li>Drug class: narcotic analgesics</li>
<li>FDA Alerts (12)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lazanda &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Duragesic, Sublimaze, Abstral, Actiq, ... +4 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Breakthrough Pain</li>
<li>Chronic Pain</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fentanyl: buccal film, buccal tablet, compounding powder, injectable solution, intravenous solution, nasal spray, oral lozenge, oral transmucosal lozenge, sublingual spray, sublingual tablet, transdermal device, transdermal film extended release</i></p><h3>General</h3><p>The most commonly reported adverse reactions included headache, nausea, vomiting, ,dizziness, and constipation.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Somnolence, dizziness</p><p><b>Common</b> (1% to 10%): Sedation, pyrexia, fatigue, lethargy, tremor, headache, chills, irritability, malaise, confusion, abnormal thinking, anxiety, dysphoria</p><p><b>Uncommon</b> (0.1% to 1%): Hyperesthesia</p><p><b>Very rare</b> (less than 0.01%): Severe hemiplegic migraine</p><p><b>Frequency not reported</b>: Slurred speech, paresthesia, hypesthesia, tremor</p><p><b>Postmarketing reports</b>: Loss of consciousness, vertigo, coma, shock, convulsion<sup>[Ref]</sup></p><p>Cases of seizures have occasionally been reported, but some investigators have suggested that the seizure-like events reported may have been episodes of fentanyl induced-rigidity.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia</p><p><b>Uncommon</b> (0.1% to 1%): Sinus tachycardia, chest pain, hypertension, hypotension, palpitations</p><p><b>Rare</b> (less than 0.1%): Arrhythmias, cardiac arrest</p><p><b>Frequency not reported</b>: Syncope, vasodilation, bradycardia, bigeminy, myocardial infarct</p><p><b>Postmarketing reports</b>: Circulatory depression<sup>[Ref]</sup></p><p>One report has suggested that epidural fentanyl may mask the pain of myocardial ischemia in patients treated with fentanyl for other reasons.  Another report has suggested that QTc interval prolongation may occur in some patients receiving the related narcotic sufentanil.  Another report has implicated fentanyl as a potential cause of pulsus alternans in a patient with aortic stenosis and congestive heart failure.</p><p></p><p>Nevertheless, fentanyl has been advocated by some as a satisfactory agent for coronary artery surgery.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (18%), vomiting (10%), constipation</p><p><b>Common</b> (1% to 10%): Dry mouth, abdominal distension, gastritis, dysphagia, dyspepsia, gastroesophageal reflux disease, ascites, hematemesis, taste perversion, abdominal pain, dehydration, anorexia, cachexia, vomiting, dry mouth, mouth ulcers/stomatitis, tongue edema </p><p><b>Uncommon</b> (0.1% to 1%): Abdomen enlarged, flatulence</p><p><b>Rare</b> (less than 0.1%): Choledochoduodenal sphincter spasm</p><p><b>Frequency not reported</b>: Diarrhea</p><p><b>Postmarketing reports</b>: Ileus, dental caries, tooth loss, gingival recession, gingivitis, gingival bleeding, lip edema, pharyngeal edema, gum bleeding, ulcer<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Urinary retention</p><p><b>Very rare</b> (less than 0.01%): Priapism</p><p><b>Frequency not reported</b>: Urinary tract infection, urination impaired, hematuria, urinary urgency, dysuria<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b>(10% or more): Iontophoretic transdermal system: Application site reaction-Erythema (14%)</p><p><b>Common</b> (1% to 10%): Application site irritation, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Hyperhidrosis, rash</p><p><b>Rare</b> (less than 0.1%): Systemic rashes</p><p><b>Frequency not reported</b>: vesicles, papules/pustules, dry and flaky skin, vesiculobullous rash wound site oozing/bleeding, wound site inflammation/erythema</p><p><b>Postmarketing reports</b>: Application site discharge, application site bleeding, application site infection, rash and scab, erosion, hyperesthesia, application site necrosis<sup>[Ref]</sup></p><p>Approximately 60% of patients had some redness at the skin site 24-hours after removal of the iontophoretic transdermal system.  The majority of skin events were categorized as mild, erythema and papules were observed; 2 patients had hyperpigmentation at the application site lasting 2 to 3 weeks; 3 patients had a rectangular mark at the application site which persisted for up to 3 months.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The hemolysis observed may have been related to rapid injection of large volumes of hypotonic fentanyl (the active ingredient contained in Lazanda) solution.  The authors therefore recommend slower injection rates and/or mixture in isotonic fluid.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Anemia, neutropenia, lymphadenopathy, thrombocytopenia, leukopenia, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood glucose increased, blood lactate increased, hypoalbuminemia, vasodilation<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Oral candidiasis, cellulitis, pneumonia, urinary tract infection, oral herpes, gastroenteritis, laryngitis</p><p><b>Very rare</b> (less than 0.01%): Recurrent herpes simplex infection following epidural administration<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Asthenia, peripheral edema, weight decreased, hypokalemia, hyponatremia, hypocalcemia</p><p><b>Very rare</b> (less than 0.01%): Syndrome of inappropriate antidiuretic hormone</p><p><b>Frequency not reported</b>: abnormal healing, dehydration<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hot flush<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Fall/accidental injury, back pain, arthralgia, joint swelling, muscular weakness, myoclonus, involuntary muscle contractions, muscle rigidity (involving the respiratory musculature including the glottis)</p><p><b>Frequency not reported</b>: Leg cramps, myalgia</p><p><b>Postmarketing reports</b>: Abnormal gait/incoordination<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Vision blurred, dry eye</p><p><b>Rare</b> (less than 0.1%): Abnormal vision<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, confusional state, hallucination, insomnia</p><p><b>Uncommon</b> (0.1% to 1%): Anxiety, agitation, restlessness, agitation, disorientation, abnormal dreams, depersonalization, depression, emotional lability, euphoria, delirium</p><p><b>Frequency not reported</b>: Nervousness<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea, rhinitis, yawning, respiratory distress, apnea, bradypnea, hypoventilation, respiratory depression</p><p><b>Uncommon</b> (0.1% to 1%): Cough, increased bronchial secretion, dysphonia, pharyngolaryngeal pain, wheezing, hypoxia, exertional dyspnea</p><p><b>Very rare</b> (less than 0.01%): Acute noncardiogenic pulmonary edema</p><p><b>Frequency not reported</b>: Asthma, hiccup, atelectasis, hyperventilation</p><p><b>Postmarketing reports</b>: Respiratory arrest<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ionsys (fentanyl)." Ortho McNeil Pharmaceutical, Raritan, NJ. </p><p id="ref_2">2. Weinger MB, Swerdlow NR, Millar WL "Acute postoperative delirium and extrapyramidal signs in a previously healthy parturient." Anesth Analg 67 (1988): 291-5</p><p id="ref_3">3. Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994): 251</p><p id="ref_4">4. Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986): 979-81</p><p id="ref_5">5. Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991): 1153-5</p><p id="ref_6">6. Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983): 858-9</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989): 852-62</p><p id="ref_9">9. Mirenda J, Tabatabai M, Wong K "Delayed and prolonged rigidity greater than 24 h following high-dose fentanyl anesthesia." Anesthesiology 69 (1988): 624-5</p><p id="ref_10">10. Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985): 205</p><p id="ref_11">11. Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982): 1020-1</p><p id="ref_12">12. Arandia HY, Patil VU "Glottic closure following large doses of fentanyl." Anesthesiology 66 (1987): 574-5</p><p id="ref_13">13. Bernstein KJ, Klausner MA "Potential dangers related to transdermal fentanyl (duragesic(r)) when used for postoperative pain." Dis Colon Rectum 37 (1994): 1339-40</p><p id="ref_14">14. Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976): 464-8</p><p id="ref_15">15. Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981): 362-3</p><p id="ref_16">16. Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983): 78</p><p id="ref_17">17. Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994): 1169-80</p><p id="ref_18">18. Crawford RD, Baskoff JD "Fentanyl-associated delirium in man." Anesthesiology 53 (1980): 168-9</p><p id="ref_19">19. Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992): 558-62</p><p id="ref_20">20. Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984): 387-8</p><p id="ref_21">21. Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990): 243-5</p><p id="ref_22">22. Hays LR, Stillner V, Littrell R "Fentanyl dependence associated with oral ingestion." Anesthesiology 77 (1992): 819-20</p><p id="ref_23">23. Streisand JB, Bailey PL, LeMaire L, Ashburn MA, Tarver SD, Varvel J, Stanley TH "Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, duration, and plasma concentrations." Anesthesiology 78 (1993): 629-34</p><p id="ref_24">24. Gil-Gouveia R,  Wilkinson PA,  Kaube H "Severe hemiplegic migraine attack precipitated by fentanyl sedation for esophagogastroscopy." Neurology 63 (2004): 2446-7</p><p id="ref_25">25. Steinberg RB, Gilman DE, Johnson F, 3d "Acute toxic delirium in a patient using transdermal fentanyl." Anesth Analg 75 (1992): 1014-6</p><p id="ref_26">26. Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991): 712</p><p id="ref_27">27. Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994): 820-1</p><p id="ref_28">28. Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987): 442-3</p><p id="ref_29">29. Oden RV, Karagianes TG "Postoperative myocardial ischemia possibly masked by epidural fentanyl analgesia." Anesthesiology 74 (1991): 941-3</p><p id="ref_30">30. Freeman AB, Steinbrook RA "Recurrence of pulsus alternans after fentanyl injection in a patient with aortic stenosis and congestive heart failure." Can Anaesth Soc J 32 (1985): 654-7</p><p id="ref_31">31. Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980): 162-3</p><p id="ref_32">32. Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982): 308-15</p><p id="ref_33">33. Sosis M "Fentanyl and emesis." Can Anaesth Soc J 32 (1985): 314-5</p><p id="ref_34">34. McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978): 437</p><p id="ref_35">35. White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992): 576-82</p><p id="ref_36">36. Gaskey NJ, Ferriero L, Pournaras L, Seecof J "Use of fentanyl markedly increases nausea and vomiting in gynecological short stay patients." AANA J 54 (1986): 309-11</p><p id="ref_37">37. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_38">38. Chin JL, Sharpe JR "Priapism and anesthesia: new considerations." J Urol 130 (1983): 371</p><p id="ref_39">39. Stoukides CA, Stegman M "Diffuse rash associated with transdermal fentanyl." Clin Pharm 11 (1992): 222</p><p id="ref_40">40. Bennett MJ, Anderson LK, McMillan JC, Ebertz JM, Hanifin JM, Hirshman CA "Anaphylactic reaction during anaesthesia associated with positive intradermal skin test to fentanyl." Can Anaesth Soc J 33 (1986): 75-8</p><p id="ref_41">41. Zucker-Pinchoff B, Ramanathan S "Anaphylactic reaction to epidural fentanyl." Anesthesiology 71 (1989): 599-601</p><p id="ref_42">42. Furuya H, Okumura F "Hemolysis after administration of high-dose fentanyl." Anesth Analg 65 (1986): 207-8</p><p id="ref_43">43. Valley MA, Bourke DL, McKenzie AM "Recurrence of thoracic and labial herpes simplex virus infection in a patient receiving epidural fentanyl." Anesthesiology 76 (1992): 1056-7</p><p id="ref_44">44. Kokko H,  Hall PD,  Afrin LB "Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion." Pharmacotherapy 22 (2002): 1188-92</p><p id="ref_45">45. Soto J, Sacristan JA, Alsar MJ "Pulmonary oedema due to fentanyl?." Anaesthesia 47 (1992): 913-4</p><p id="ref_46">46. Bohrer H, Fleischer F, Werning P "Tussive effect of a fentanyl bolus administered through a central venous catheter." Anaesthesia 45 (1990): 18-21</p><p id="ref_47">47. Tweed WA, Dakin D "Explosive coughing after bolus fentanyl injection." Anesth Analg 92 (2001): 1442-3</p><p id="ref_48">48. Ananthanarayan C "Tussive effect of fentanyl." Anaesthesia 45 (1990): 595</p><p id="ref_49">49. Phua WT, Teh BT, Jong W, Lee TL, Tweed WA "Tussive effect of a fentanyl bolus." Can J Anaesth 38 (1991): 330-4</p><h2>More about Lazanda (fentanyl)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En EspaÃ±ol</li>
<li>2 Reviews</li>
<li>Drug class: narcotic analgesics</li>
<li>FDA Alerts (12)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lazanda &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breakthrough Pain</li>
<li>Chronic Pain</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>